AnaptysBio Inc - Company Profile
Powered by 
All the sales intelligence you need on AnaptysBio Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how AnaptysBio Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with AnaptysBio Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
AnaptysBio Inc (Anaptys) is a clinical-stage biotechnology company. It is focused on advancing immune cell-modulating antibodies for autoimmune and inflammatory diseases. The company's product candidates include rosnilimab, a PD-1 agonist in trials for rheumatoid arthritis, and ANB032, a BTLA agonist in development for atopic dermatitis. Its preclinical pipeline features ANB033, targeting CD122 to manage inflammation, and ANB101, a BDCA2 modulator to regulate dendritic cells. The company is also advancing cytokine antagonists imsidolimab, targeting IL-36R for generalized pustular psoriasis, and etokimab, an IL-33 antagonist. Anaptys is headquartered in San Diego, California, the US..
Headquarters
United States of America
Address
Suite 210, 10770 Wateridge Circle, San Diego, California, 92121
Website
www.anaptysbio.com
Telephone
1 302 6587581
No of Employees
104
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ANAB (NASD)
Revenue (2024)
$234.6M
157%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
90.9%
(2024 vs 2023)
Market Cap*
$1.6B
Net Profit Margin (2024)
XYZ
96.5%
(2024 vs 2023)
* As of and is in US$
AnaptysBio Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| ANB032: Atopic Dermatitis |
| Rosnilimab: Rheumatoid Arthritis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In February, the company entered into a contract with Vanda Pharmaceuticals for the development and commercialization of imsidolimab. |
| 2023 | Contracts/Agreements | In November, the company entered into an exclusive license agreement with Centessa Pharmaceuticals for its blood dendritic cell antigen 2 (BDCA2) modulator antibody. |
| 2021 | Contracts/Agreements | In October, the company entered into an agreement with Sagard Healthcare Royalty Partners to monetize a portion of AnaptysBio’s future JEMPERLI royalties and milestones. |
Competitor Comparison
| Key Parameters | AnaptysBio Inc | Eli Lilly and Co | Pfizer Inc | AbbVie Inc | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
| City | San Diego | Indianapolis | New York City | North Chicago | Cambridge |
| State/Province | California | Indiana | New York | Illinois | Cambridgeshire |
| No. of Employees | 104 | 50,605 | 75,000 | 57,000 | 96,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John Orwin | Chairman | Executive Board | 2023 | 64 |
| Daniel Faga | Chief Executive Officer; Director; President | Executive Board | 2023 | 46 |
| Dennis Mulroy | Chief Financial Officer | Senior Management | 2020 | 71 |
| Eric Loumeau | Chief Legal Officer | Senior Management | 2023 | 63 |
| Paul F. Lizzul, M.D., Ph.D. | Chief Medical Officer | Senior Management | 2020 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer